Adaptive Biotechnologies (ADPT) says new blood‑cancer clinical guidelines from NCCN and ASCO now call for repeat minimal residual disease (MRD) testing using its clonoSEQ assay. The recommendations cover multiple hematologic malignancies and could broaden test adoption, driving higher order volumes.
The announcement nudges ADPT stock higher as investors price in incremental recurring revenue. Sentiment turns mildly bullish, lifting biotech‑sector momentum, though upside remains capped by execution and reimbursement risk. Capital may shift toward ADPT and peer biotech names.
Analyzed by FNXT Experts